Submit a Review & Earn an Amazon Gift Card
You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!
Submit ReviewNGD 98-2 hydrochloride is a high affinity antagonist of corticotropin-releasing factor receptor 1 (CRF1) (Ki = 1 nM). Orally available and brain penetrant.
M. Wt | 435.87 |
Formula | C19H24F3N3O3.HCl |
Storage | Desiccate at RT |
Purity | ≥98% (HPLC) |
PubChem ID | 90488929 |
InChI Key | KUZDADGRZQAQGN-UHFFFAOYSA-N |
Smiles | CC1=NC(NC(CC)CC)=C(OC)N=C1C2=CC=C(OC(F)(F)F)C=C2OC.Cl |
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
References are publications that support the biological activity of the product.
Hodgetts et al (2011) Discovery of N-(1-ethylpropyl)-[3-methoxy-5-(2-methoxy-4-trifluoromethoxyphenyl)-6-methyl-pyrazin-2-yl]amine 59 (NGD 98-2): an orally active cortico. releasing factor-1 (CRF-1) receptor antagonist. J.Med.Chem. 54 4187 PMID: 21618986
Keywords: NGD 98-2 hydrochloride, NGD 98-2 hydrochloride supplier, NGD982, corticotrophin, corticotropin-release, releasing, factor, receptors, antagonists, CFR-1, CRF1, high, affinity, Receptors, 4315, Tocris Bioscience
Citations are publications that use Tocris products.
Currently there are no citations for NGD 98-2 hydrochloride.
There are currently no reviews for this product. Be the first to review NGD 98-2 hydrochloride and earn rewards!
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
Major depressive disorder is characterized by depressed mood and a loss of interest and/or pleasure. Updated in 2015 this poster highlights presynaptic and postsynaptic targets for the potential treatment of major depressive disorder, as well as outlining the pharmacology of currently approved antidepressant drugs.